Back to top

pharmaceuticals: Archive

Zacks Equity Research

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

GILDPositive Net Change VRTXPositive Net Change INCYNegative Net Change MRNAPositive Net Change OPKPositive Net Change

Zacks Equity Research

Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat

Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.

ALKSPositive Net Change VRTXPositive Net Change CARAPositive Net Change VIRPositive Net Change

Zacks Equity Research

Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change VIRPositive Net Change

Zacks Equity Research

Best Growth Stocks to Buy for January 27th

TOL, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 27, 2022

PFEPositive Net Change MPositive Net Change TOLNegative Net Change

Zacks Equity Research

Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

LGNDPositive Net Change ICPTPositive Net Change VKTXPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck

Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.

REGNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

REGNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change GILDPositive Net Change

Zacks Equity Research

Waters (WAT) to Report Q4 Earnings: What's in the Cards?

Waters' (WAT) fourth-quarter 2021 results are likely to reflect solid momentum across pharmaceutical and industrial end markets.

WATPositive Net Change AMEPositive Net Change MPWRPositive Net Change DAVAPositive Net Change

Zacks Equity Research

SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study

Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.

REGNPositive Net Change GSKPositive Net Change LLYPositive Net Change SABSNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips

Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.

RHHBYNegative Net Change STMPositive Net Change PFEPositive Net Change PHGPositive Net Change BAXPositive Net Change

Zacks Equity Research

Markets Await More Earnings Data

Markets Await More Earnings Data

GEPositive Net Change JNJPositive Net Change

Zacks Equity Research

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

REGNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change GILDPositive Net Change

Zacks Equity Research

Best Growth Stocks to Buy for January 25th

CROX, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 25, 2022

PFEPositive Net Change MPositive Net Change CROXPositive Net Change

Zacks Equity Research

New Strong Sell Stocks for January 25th

APPN, AZN, and GRWG have been added to the Zacks Rank #5 (Strong Sell) List on January 25, 2022

AZNPositive Net Change APPNPositive Net Change GRWGPositive Net Change

Zacks Equity Research

Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

PFEPositive Net Change ALKSPositive Net Change OPKPositive Net Change ASNDNo Net Change

Sheraz Mian

Top Research Reports for Microsoft, Visa & Cisco

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Visa Inc. (V), and Cisco Systems, Inc. (CSCO).

MSFTPositive Net Change VPositive Net Change CSCOPositive Net Change LLYPositive Net Change TMOPositive Net Change BRK.BPositive Net Change

Zacks Equity Research

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

RHHBYNegative Net Change PFEPositive Net Change VRTXPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Best Growth Stocks to Buy for January 24th

WLK, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 24, 2022

WLKPositive Net Change PFEPositive Net Change MPositive Net Change

Zacks Equity Research

Regeneron (REGN) Rides on Solid Product Portfolio: Should You Buy?

Regeneron (REGN) is expected to maintain momentum on the back of a solid and diverse portfolio. The promising pipeline also sets the stage for further growth.

REGNPositive Net Change SNYPositive Net Change RHHBYNegative Net Change BAYRYNo Net Change

Kinjel Shah

Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE

Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.

SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change PFEPositive Net Change ABBVPositive Net Change

Zacks Equity Research

J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.

GSKPositive Net Change JNJPositive Net Change AMGNPositive Net Change ABBVPositive Net Change

Zacks Equity Research

Best Growth Stocks to Buy for January 21st

PFE, M, and ARCB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 21, 2022

PFEPositive Net Change MPositive Net Change ARCBPositive Net Change

Nalak Das

6 Must-Buy Large-Cap Stocks Ahead of Q4 Earnings Next Week

Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.

STLDPositive Net Change FCXPositive Net Change VRTXPositive Net Change BROPositive Net Change TSLANegative Net Change URIPositive Net Change

Zacks Equity Research

Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

REGNPositive Net Change SNYPositive Net Change PFEPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More

Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.

REGNPositive Net Change ZGNXPositive Net Change BLUEPositive Net Change GMDANegative Net Change